Replies to post #1536 on NorthWest Biotherapeutics Inc (NWBO)

[a1derfullife]

IMUC vs NWBO

Seems a little simplistic to me to talk about IMUC only being in ph 2 and NWBO being in ph 3. IMUC has 278 patients enrolled in their ph 2 study, whereas NWBO will have a total of 300 in their phase 3 study. If NWBO will truly not finish enrolling until Q4 2014, they will likely not have top line results until the end of 2015 - a full 2 years after IMUC has top line results. Given the number of patients in IMUC's ph 2 study, IMO it's likely that their drug will be approved if their phase 2 results are similar to their phase 1 results, simply because the phase 1 results showed such a huge improvement over the current std of care (ie, there's a pressing unmet need in the treatment of GBM, so the first drug with impressive ph 2 or ph 3 results will likely be fast tracked for approval).

A1

[john1045]

In yesterday's presentation on Slide 2, she highlighted a a number of milestones with DCVax-L for GBM and NWBO reaching first interim analysis in the by trial end of Q2 or Q3 2013. In Slide 14, highlights 6-month of progression free survival to meet primary endpoint of trial-only 1/3 as long as extension of PFS seen in Phase I/II trials.

The DCVax-Direct Phase I/II "All Comers" trial is progressing for patients with colon, liver, pancreas, melanoma & misc.with key endpoints Safety & Tumor Regression. If NWBO shows striking results from terminal patients with inoperable tumors they hit the pall out of the park immediately as they expect to have results in this trial in 1H of 2013.